secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioXcel Therapeutics, Inc. (BTAI)
CIK:        0001720893
Form:       8-K
Filed at:   2025-08-11T23:59:59+00:00
Accession:  0001104659-25-076214
Event type: debt
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioXcel Therapeutics raises $30.4M net, satisfies Oaktree financing covenant
----------------------------------------------------------------------------

- Raised $30.4M net from Nov 2024 ($6.2M), Mar 2025 ($13.0M), and ATM ($11.2M) financings, satisfying the Oaktree Financing Covenant.
- Covenant required $29M net by Aug 15, 2025 or 30 days after SERENITY Phase 3 final readout; now satisfied.
- As of Aug 8, 2025, BioXcel had 13,709,124 shares outstanding post-exercise of all pre-funded warrants.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1720893/000110465925076214/0001104659-25-076214-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1720893/000110465925076214/tm2523144d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-076214

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer